Go Pro
→ Elon gets it. Do you? (From Porter & Company) (Ad)tc pixel Free CAPS Stock Alerts

Capstone Therapeutics (CAPS) Competitors

Capstone Therapeutics logo
$0.20 +0.03 (+14.17%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$0.17 -0.03 (-16.58%)
As of 07:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CAPS vs. CLWT, SOS, JBDI, MWG, and INEO

Should you buy Capstone Therapeutics stock or one of its competitors? Capstone Therapeutics's main competitors and comparable companies include Euro Tech (CLWT), SOS (SOS), JBDI (JBDI), Multi Ways (MWG), and INNEOVA (INEO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "trading companies & distributors" industry.

How does Capstone Therapeutics compare to Euro Tech?

Capstone Therapeutics (NASDAQ:CAPS) and Euro Tech (NASDAQ:CLWT) are both small-cap industrials companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Euro Tech has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. Euro Tech's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-36.51% -144.43% -40.48%
Euro Tech N/A N/A N/A

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of Euro Tech shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Comparatively, 79.0% of Euro Tech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Capstone Therapeutics had 1 more articles in the media than Euro Tech. MarketBeat recorded 1 mentions for Capstone Therapeutics and 0 mentions for Euro Tech. Capstone Therapeutics' average media sentiment score of 0.00 equaled Euro Tech'saverage media sentiment score.

Company Overall Sentiment
Capstone Therapeutics Neutral
Euro Tech Neutral

Euro Tech has lower revenue, but higher earnings than Capstone Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.09-$21.23M-$3.35N/A
Euro Tech$13.27M0.84$160KN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Euro Tech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Capstone Therapeutics has a beta of -1.5, indicating that its stock price is 250% less volatile than the broader market. Comparatively, Euro Tech has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Summary

Euro Tech beats Capstone Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Capstone Therapeutics compare to SOS?

SOS (NYSE:SOS) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap industrials companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Capstone Therapeutics has lower revenue, but higher earnings than SOS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOS$154.29M0.04-$97.32MN/AN/A
Capstone Therapeutics$48.11M0.09-$21.23M-$3.35N/A

1.9% of SOS shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 2.7% of SOS shares are held by insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

SOS has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. SOS's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SOSN/A N/A N/A
Capstone Therapeutics -36.51%-144.43%-40.48%

In the previous week, SOS had 3 more articles in the media than Capstone Therapeutics. MarketBeat recorded 4 mentions for SOS and 1 mentions for Capstone Therapeutics. SOS's average media sentiment score of 0.00 equaled Capstone Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOS
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Capstone Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOS
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

SOS has a beta of 2.6, meaning that its stock price is 160% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.5, meaning that its stock price is 250% less volatile than the broader market.

Summary

SOS beats Capstone Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Capstone Therapeutics compare to JBDI?

JBDI (NASDAQ:JBDI) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap industrials companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

2.6% of Capstone Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

JBDI has a beta of -1.11, meaning that its stock price is 211% less volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.5, meaning that its stock price is 250% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
JBDI
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, JBDI had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 2 mentions for JBDI and 1 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 0.00 beat JBDI's score of -0.34 indicating that Capstone Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
JBDI
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Capstone Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

JBDI has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. JBDI's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
JBDIN/A N/A N/A
Capstone Therapeutics -36.51%-144.43%-40.48%

JBDI has higher earnings, but lower revenue than Capstone Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JBDI$8.52M1.24$120KN/AN/A
Capstone Therapeutics$48.11M0.09-$21.23M-$3.35N/A

Summary

JBDI beats Capstone Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Capstone Therapeutics compare to Multi Ways?

Multi Ways (NYSE:MWG) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap industrials companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Multi Ways
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

0.8% of Multi Ways shares are owned by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Multi Ways has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.5, indicating that its share price is 250% less volatile than the broader market.

Multi Ways has higher earnings, but lower revenue than Capstone Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Multi Ways$44.77M0.15$1.79MN/AN/A
Capstone Therapeutics$48.11M0.09-$21.23M-$3.35N/A

In the previous week, Multi Ways had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 2 mentions for Multi Ways and 1 mentions for Capstone Therapeutics. Multi Ways' average media sentiment score of 0.00 equaled Capstone Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Multi Ways
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Capstone Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Multi Ways has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. Multi Ways' return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Multi WaysN/A N/A N/A
Capstone Therapeutics -36.51%-144.43%-40.48%

Summary

Multi Ways beats Capstone Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Capstone Therapeutics compare to INNEOVA?

Capstone Therapeutics (NASDAQ:CAPS) and INNEOVA (NASDAQ:INEO) are both small-cap industrials companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Capstone Therapeutics has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market. Comparatively, INNEOVA has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

INNEOVA has higher revenue and earnings than Capstone Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.09-$21.23M-$3.35N/A
INNEOVA$58.42M0.11-$400KN/AN/A

In the previous week, Capstone Therapeutics had 1 more articles in the media than INNEOVA. MarketBeat recorded 1 mentions for Capstone Therapeutics and 0 mentions for INNEOVA. Capstone Therapeutics' average media sentiment score of 0.00 equaled INNEOVA'saverage media sentiment score.

Company Overall Sentiment
Capstone Therapeutics Neutral
INNEOVA Neutral

INNEOVA has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. INNEOVA's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-36.51% -144.43% -40.48%
INNEOVA N/A N/A N/A

2.6% of Capstone Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
INNEOVA
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

INNEOVA beats Capstone Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Capstone Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CAPS vs. The Competition

Export
MetricCapstone TherapeuticsTrading Companies & Distributors IndustryIndustrials SectorNASDAQ Exchange
Market Cap$3.67M$9.41B$10.31B$13.29B
Dividend YieldN/A3.42%96.94%12.57%
P/E Ratio-0.0627.4325.5825.69
Price / Sales0.0923.33281.1478.99
Price / CashN/A49.7224.1052.76
Price / Book0.153.854.896.32
Net Income-$21.23M$373.13M$614.63M$359.73M
7 Day Performance11.67%1.41%0.68%0.17%
1 Month Performance8.29%-1.39%-2.31%-3.27%
1 Year Performance-84.20%7.01%4.38%5.58%

Capstone Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CAPS
Capstone Therapeutics
0.851 of 5 stars		$0.20
+14.2%		N/A-84.3%$3.67M$48.11MN/A93
CLWT
Euro Tech
0.6591 of 5 stars		$1.52
-1.3%		N/A+13.2%$11.47M$13.27MN/A24
SOS
SOS
0.3632 of 5 stars		$0.77
+10.4%		N/A-85.2%$11.26M$154.29MN/A51
JBDI
JBDI
0.4463 of 5 stars		$1.10
+1.9%		N/A-69.8%$10.28M$8.52MN/A99
MWG
Multi Ways
N/A$1.27
-4.5%		N/A-57.7%$6.52M$44.77MN/A56

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CAPS) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel